Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to $3.6 million.

  • Anika Therapeutics' Change in Accured Expenses rose 64.09% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 28.80%. This contributed to the annual value of -$3.7 million for FY2024, which is 322.63% down from last year.
  • Per Anika Therapeutics' latest filing, its Change in Accured Expenses stood at $3.6 million for Q3 2025, which was up 266.90% from -$2.2 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Change in Accured Expenses high stood at $4.6 million for Q3 2023, and its period low was -$4.3 million during Q2 2023.
  • In the last 3 years, Anika Therapeutics' Change in Accured Expenses had a median value of -$935,000 in 2024 and averaged -$332,909.
  • Per our database at Business Quant, Anika Therapeutics' Change in Accured Expenses soared by 287.22% in 2021 and then plummeted by 567.67% in 2024.
  • Over the past 5 years, Anika Therapeutics' Change in Accured Expenses (Quarterly) stood at $406,000 in 2021, then slumped by 237.44% to -$558,000 in 2022, then soared by 231.54% to $734,000 in 2023, then crashed by 227.38% to -$935,000 in 2024, then surged by 64.09% to $3.6 million in 2025.
  • Its Change in Accured Expenses stands at $3.6 million for Q3 2025, versus -$2.2 million for Q2 2025 and -$3.1 million for Q1 2025.